Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12609000232235
ACTRN12609000232235
Recruiting
Not Applicable

Randomised, double blind, placebo controlled, cross over study to investigate the effect of dietary supplementation with coenzyme Q10 on endothelial function in males with the metabolic syndrome who are concurrently on statin treatment.

ipid and Diabetes Research Group0 sites30 target enrollmentMay 8, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDyslipidemiaMetabolic and Endocrine - Metabolic disordersCardiovascular - Diseases of the vasculature and circulation including the lymphatic system

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Dyslipidemia
Sponsor
ipid and Diabetes Research Group
Enrollment
30
Status
Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 8, 2009
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
ipid and Diabetes Research Group

Eligibility Criteria

Inclusion Criteria

  • •Waist circumference \>\= 94cm
  • •Triglycerides \>\=1\.7 mmol/L or specific therapy for tirglycerides
  • •Systolic blood presure \>\=130 mmHg or Diastolic blood pressure \>\=85 mmHg or treatment for hypertension
  • •Statin naive or treatment with \<\=40mg/day simvastatin or equivalent

Exclusion Criteria

  • •Pre\-treatment Low\-density Lipoprotein (LDL)\-cholesterol \<1\.5mmol/L or \>6\.5 mmol/L
  • •Pre\-treatment triglycerides \>5 mmol/L
  • •History of cardiovascular event or intervention within the 6 months prior to screening
  • •Type 1 diabetes mellitus
  • •Type 2 diabetes mellitus requiring oral anti\-diabetic agents or insulin
  • •Current smoker
  • •Treatment with fibrates or other lipid modifying agents other than statin therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Clinical study with randomly into groups divided patients (investigational or ineffective control medication), where neither the doctor nor the patient's know the assignment, to determine the effect of the investigational product (Empagliflozin) on the circulation in the smallest vessels of the body.Type 2 diabetes mellitusMedDRA version: 17.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2014-003053-34-DEIPPMed – Institut für Pharmakologie und Präventive Medizin GmbH
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.Duchenne Muscular Dystrophy (DMD)MedDRA version: 19.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2016-000401-36-ITITALFARMACO S.p.A.192
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.
EUCTR2016-000401-36-GBITALFARMACO S.p.A.169
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.
EUCTR2016-000401-36-ESITALFARMACO S.p.A.192
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.
EUCTR2016-000401-36-DEITALFARMACO S.p.A.169